Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
about
Chapter 14: Cancer genome analysisPatient-derived tumour xenografts as models for oncology drug developmentTargeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugsRecent progress in pancreatic cancerClinical Genetic Testing in GastroenterologyGenomic alterations in pancreatic cancer and their relevance to therapyMolecular landscape of pancreatic cancer: implications for current clinical trialsGenetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencingOne mouse, one patient paradigm: New avatars of personalized cancer therapyCIViC databaseDevelopment and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinomaA Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In VivoAdvances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Whole-exome sequencing of pancreatic neoplasms with acinar differentiationUnique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsPancreatic cancer genomics: insights and opportunities for clinical translationPancreatic biomarkers: could they be the answer?Personalising pancreas cancer treatment: When tissue is the issue.The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer CellsGenomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.PLoS Computational Biology Conference Postcards from ISMB/ECCB 2011.Therapeutic options for the management of pancreatic cancer.A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancerMetabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer.Smarter drugs emerging in pancreatic cancer therapy.Patient-derived xenografts for individualized care in advanced sarcoma.Organoid models of human and mouse ductal pancreatic cancerClinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patientsQuality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial.Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancerGenomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genesDrug therapy for hereditary cancersVery Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing AnalysisPathological and molecular evaluation of pancreatic neoplasms.Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Hereditary pancreatic and hepatobiliary cancersThe promise and challenge of ovarian cancer models.
P2860
Q21145309-C4EF1BA3-FF60-44CE-9845-4486CC1FA17FQ24604068-EBFC2D62-ECDE-46F3-B907-DC0AE9C17862Q24610287-32E08D7B-4ED0-43A7-9FF5-BFED43B34888Q24626346-2B066B30-A29D-46DA-A74E-0D48C51DD4AEQ26749157-04FE4BA4-4987-4E5A-9046-5BD1438BD9C5Q26781443-FAB77238-FAB0-49C9-937B-497B57C15B77Q26824528-7AF998C6-D40C-4984-B327-0A686AAF461BQ26991615-425827AB-F769-48A8-82E3-2D2537589A29Q27023342-8B2B4717-E04E-43AB-B298-94AAB244F50FQ27612411-0CE104E2-1FAD-4CB0-BE80-12955FDB3659Q28534618-E6388047-8F8A-4F60-9AE8-E40A6D8DF0E4Q28552262-0FF4B878-52FC-424B-838E-BB7A3E7C8E52Q30423597-4CCEB085-CAD2-4EBB-B996-70AA6AE58A83Q33720718-21834C55-B9D0-4456-8B18-C63C2CEF2C2DQ33756991-A464FE26-BC02-4C8C-BEB7-9B405C727D56Q33781071-2773A28D-75A9-42EA-9D6F-32D2716DFD9BQ33801371-81695B52-7695-46D8-BD37-A4ADFF1EC874Q33801384-ECF1FD25-9E1A-4E9F-9D80-92F802FD0D97Q33826323-7C331507-2017-4A71-B224-F725C2B92057Q33888432-0CE2866C-4B2E-4D68-92CF-BD2E49A657D7Q34085584-D34B5B0B-B070-4779-8A8F-879C0FE4F45DQ34093776-C0532082-667F-4D1A-A115-F45823CBE38DQ34192568-D55D3D78-C2EB-4FEF-B8B7-4246A9F43F58Q34292602-36A540A7-7B8F-4236-B1F8-4FCAAE3041BDQ34410212-321BB633-3A22-4E1B-8F10-14E2FBD22998Q34413869-D24A6813-F4AF-4077-9EF2-D32F9ACF3B04Q34456438-EBAF4CC4-6F49-40C3-B5F2-D8746E095D65Q34483980-B9096B70-F855-4786-9C1B-0D465B5BA0D5Q34484260-029EA66A-BF5F-47E5-997B-3EC52A497588Q34657038-4AAA7D1B-BCDF-4A62-B03D-4F22FEA7E7C2Q35051154-FF08FDB3-CC6A-49EA-86EF-6581369305D5Q35067532-6F3A1905-47F9-46A1-B72F-E9229DA3F93DQ35079022-A4757590-CBF1-4E4A-AC5C-243200118532Q35160677-6DA392A3-9D6D-4281-BC1E-6FD95C88A8F1Q35208929-466B1DE9-6BED-459D-BFFF-913CCD0217F0Q35463399-3B22317A-50C5-4D70-944C-C98BD246B903Q35670143-32A47898-BE68-4791-8230-9BE9A21D1D78Q35684995-5BDC498B-7FB0-445B-A1EC-3476C162D60EQ35692230-2F3F99EB-1A3C-43BE-BC3E-0BDD6C33D0FCQ35771750-527720E0-29A1-4153-B1D3-8AD291CB72CD
P2860
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@ast
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@en
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@nl
type
label
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@ast
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@en
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@nl
altLabel
Personalizing Cancer Treatment ...... ng Agents in Pancreatic Cancer
@en
prefLabel
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@ast
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@en
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@nl
P2093
P2860
P50
P3181
P1476
Personalizing cancer treatment ...... g agents in pancreatic cancer.
@en
P2093
Alison Klein
Ana De Jesus-Acosta
Anirban Maitra
Daniel Laheru
James R Eshleman
Manuel Hidalgo
Maria C Villarroel
N V Rajeshkumar
Ross Donehower
P2860
P3181
P356
10.1158/1535-7163.MCT-10-0893
P577
2011-01-01T00:00:00Z